Literature DB >> 12692538

The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion.

Lee-Wei Chen1, Laurence Egan, Zhi-Wei Li, Florian R Greten, Martin F Kagnoff, Michael Karin.   

Abstract

We studied the role of NF-kappaB in acute inflammation caused by gut ischemia-reperfusion through selective ablation of IkappaB kinase (IKK)-beta, the catalytic subunit of IKK that is essential for NF-kappaB activation. Ablation of IKK-beta in enterocytes prevented the systemic inflammatory response, which culminates in multiple organ dysfunction syndrome (MODS) that is normally triggered by gut ischemia-reperfusion. IKK-beta removal from enterocytes, however, also resulted in severe apoptotic damage to the reperfused intestinal mucosa. These results show the dual function of the NF-kappaB system, which is responsible for both tissue protection and systemic inflammation, and underscore the caution that should be exerted in using NF-kappaB and IKK inhibitors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12692538     DOI: 10.1038/nm849

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  177 in total

1.  Conditional ablation of Ikkb inhibits melanoma tumor development in mice.

Authors:  Jinming Yang; Ryan Splittgerber; Fiona E Yull; Sara Kantrow; Gregory D Ayers; Michael Karin; Ann Richmond
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

Review 2.  Role of T cell-nuclear factor κB in transplantation.

Authors:  Luciana L Molinero; Maria-Luisa Alegre
Journal:  Transplant Rev (Orlando)       Date:  2011-11-08       Impact factor: 3.943

3.  Toll-like receptor signaling during myocardial ischemia.

Authors:  Tobias Eckle; Holger K Eltzschig
Journal:  Anesthesiology       Date:  2011-03       Impact factor: 7.892

4.  An endogenously anti-inflammatory role for methylation in mucosal inflammation identified through metabolite profiling.

Authors:  Douglas J Kominsky; Simon Keely; Christopher F MacManus; Louise E Glover; Melanie Scully; Colm B Collins; Brittelle E Bowers; Eric L Campbell; Sean P Colgan
Journal:  J Immunol       Date:  2011-04-22       Impact factor: 5.422

Review 5.  NF-kappaB in critical diseases: a bad guy?

Authors:  Uwe Senftleben
Journal:  Intensive Care Med       Date:  2003-09-04       Impact factor: 17.440

Review 6.  Bacterial inhibition of eukaryotic pro-inflammatory pathways.

Authors:  Andrew S Neish
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 7.  The nuclear factor NF-kappaB pathway in inflammation.

Authors:  Toby Lawrence
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10-07       Impact factor: 10.005

8.  Small β2-glycoprotein I peptides protect from intestinal ischemia reperfusion injury.

Authors:  Michael R Pope; Urska Bukovnik; John M Tomich; Sherry D Fleming
Journal:  J Immunol       Date:  2012-10-03       Impact factor: 5.422

9.  Nuclear factor-kappaB1 (p50) limits the inflammatory and fibrogenic responses to chronic injury.

Authors:  Fiona Oakley; Jelena Mann; Sarah Nailard; David E Smart; Narendra Mungalsingh; Christothea Constandinou; Shakir Ali; Susan J Wilson; Harry Millward-Sadler; John P Iredale; Derek A Mann
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

10.  Flagellin suppresses epithelial apoptosis and limits disease during enteric infection.

Authors:  Matam Vijay-Kumar; Huixia Wu; Rheinallt Jones; George Grant; Brian Babbin; Timothy P King; Denise Kelly; Andrew T Gewirtz; Andrew S Neish
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.